2月21日 - ** 周五，AlvotechALVO.O上涨5.4%，Teva PharmaceuticalsTTEVA.TA美股下跌1.2%，因为这两家公司称在美国推出了强生JNJ.NStelara的生物仿制药。
** 继1月份安进公司AMGN.O推出Wezlana之后， (link)，这标志着Stelara的第二个生物仿制药上市，预计Biocon BiologicsBIOC.NS和费森尤斯卡比公司FRES.M3将很快跟进。 ** 瑞银（UBS）分析师认为，新产品的推出是未来生物仿制药的成功之路；预计到 2028 年，全球销售额将达到 3.9 亿美元 ** ALVO的股价今年以来下跌了约7%，而TEVA下跌了24%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.